A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease - Wikidata - wikimedia - TriplyDB

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

http://www.wikidata.org/entity/Q58202813

about

Recent developments in Alzheimer's disease therapeutics Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease Novel therapeutics for Alzheimer's disease: an update Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention The role of tau in neurodegenerative diseases and its potential as a therapeutic target Tau-targeted treatment strategies in Alzheimer's disease Spines, plasticity, and cognition in Alzheimer's model mice Tau Biology and Tau-Directed Therapies for Alzheimer's Disease Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model.A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models Peptides for therapy and diagnosis of Alzheimer's disease.Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.Advances in tau-based drug discovery.Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies.The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.Soluble forms of tau are toxic in Alzheimer's disease.Tau-based treatment strategies in neurodegenerative diseases Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.The multiple mechanisms of amyloid deposition: the role of parkin.Microtubule stabilising peptides rescue tau phenotypes in-vivo.Novel therapeutics based on tau/microtubule dynamics: WO2008084483.Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.Current therapeutic targets for the treatment of Alzheimer's disease.Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures.The role of tau in Alzheimer's disease and related disorders.

P2860

Q21245264-56CA0657-F6B1-4F72-99D8-9C47FC33B1AF Q21262018-8CCE0F49-992B-4DB9-8764-3C36B8D8A4DA Q24620383-F0EA6EB3-A31E-46AD-ACD5-F381901BBA01 Q26739412-8FF5FB8D-22A2-4A53-B56D-8E3CC73C08CE Q26859305-2486AA27-026D-4897-B1DB-152884FB86E9 Q26861683-1E02F6B9-B87F-48B6-A6EE-D0FAFC935F92 Q26865358-AEFA3F2D-01FC-4082-A622-EFEB02A3F5FE Q27005032-B97A59AD-12F9-4A4B-8E85-6D79AF88D02E Q27023429-D3579C01-55A1-4F90-8368-9ECC377EE052 Q27691328-EDB4DB97-0AD7-4732-9F56-D42E7D134328 Q28071398-DC85F577-ED81-462B-B88C-E35D6950E154 Q28247764-A879022D-A89E-493F-9B30-EE2F91D4F3E9 Q28743487-2772545A-2883-4C44-B1EA-86823A239154 Q30540857-794A2F91-DBAB-41AD-8A7C-6F140C8DCD11 Q33393912-652329E8-F1B8-4469-B2EA-E16C18DF3ADF Q33705188-B61D1BC1-8AE6-4979-9130-0D95BED49B41 Q33828966-EBB69F2C-DE8A-49CF-A2BE-3D86621EC774 Q33865294-14FC4BD3-47CD-4AA8-B487-B0331557EAB1 Q34068459-1714C8AB-A1B9-474F-BDBA-D9EE35399438 Q34124260-AB1D885D-5EBF-40CD-B940-DFF9FAF35812 Q34292532-562C81DC-931E-49F8-87CD-F833152C2AA4 Q34378321-8F508E53-5A51-4E10-BDC8-8AE2E4CB5913 Q34505647-018A2466-4CA3-45F6-878E-9D857874A428 Q34525286-BC11FB66-7F64-49CF-B257-88CEBF906CEC Q34612993-4C349BF9-5055-4895-AA3F-A8A0FC745855 Q35107027-B6D20A41-26CC-4B63-8873-60323A99639E Q35321539-5DFD0E42-782E-445F-B38C-003057A117F1 Q35653810-C3173EA0-7DFC-41B5-882C-98460CB1AEDA Q35875920-D4B62171-CEBE-48A2-8D12-AE21B3890075 Q36231741-B4F5463D-67BC-4179-A996-5CD8FFA08E4E Q36286360-9CB9D534-47DC-409D-BC9C-614BB41070C2 Q37215861-86C62FC9-F5AA-41C1-8725-75D9F110B3B5 Q37313065-E7C8AC17-06F9-4B2F-9A26-C80CBFC6A98E Q37409163-9D059F43-9DC4-4B84-9418-E9F5710EEB09 Q37464820-3E76F964-8CA8-4324-A337-E9D71C9F8375 Q37530885-824BDA7D-83BA-43DA-A08B-621B9EBCB635 Q37606284-A34BD23C-A2FE-403E-87F5-247BEA4FC00B Q37737296-1A71D495-E700-4605-8ABF-39AE580C88A6 Q37745627-482FAB26-6AEA-4AAE-9DD2-BEB4399EA3EB Q37765632-5398CD71-6CFB-4A47-B19F-F791DC21CE0D

P2860

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

http://www.wikidata.org/entity/Q58202813

description

article

@en

im Januar 2008 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2008

@uk

name

A Neuronal Microtubule-Interac ...... e Model of Alzheimer's Disease

@en

A Neuronal Microtubule-Interac ...... e Model of Alzheimer's Disease

@nl

type

label

A Neuronal Microtubule-Interac ...... e Model of Alzheimer's Disease

@en

A Neuronal Microtubule-Interac ...... e Model of Alzheimer's Disease

@nl

prefLabel

A Neuronal Microtubule-Interac ...... e Model of Alzheimer's Disease

@en

A Neuronal Microtubule-Interac ...... e Model of Alzheimer's Disease

@nl

P1433

Q58202813-81F160C8-7824-4E57-B4F7-C5EE16471403

P1476

Q58202813-D5E6EA7E-F777-4891-A331-A0035A303B0D

P2093

Q58202813-07284FD5-4396-4230-ABBB-4DED44669797

Q58202813-12CC14DE-519E-4A6B-8D2A-4B7A52B2D6F2

Q58202813-6AE25033-7063-4446-9BDC-432898535CDC

Q58202813-6F5C0ED2-E543-4A9C-A839-C054FA1ADD84

Q58202813-70741C67-D072-40DA-8DFF-B4D3277E9839

Q58202813-7C9114DF-AF76-4C05-8D5B-5A6E4C428CEE

Q58202813-875CE68E-2009-4E05-9535-3AC3E6F778DD

Q58202813-92A8B576-BB5A-4BFA-B7CE-07D5DC13B9DF

Q58202813-F3918B74-DDD3-4573-962E-EE43D983C2AD

Q58202813-FFA5CDB8-6F57-4BB2-BFBB-E55F181202DE

P304

Q58202813-34423F6B-60DA-4D07-9B14-D7F50694F7BB

P31

Q58202813-0DEC031A-BA69-40F1-B2F6-F6CE8E608306

P356

Q58202813-1FFBFF78-179D-48B5-867D-8FC89F38C47D

P407

Q58202813-4CE7F852-7871-4052-9E53-13ED166629C4

P433

Q58202813-66AA900B-2E90-43C9-B3D0-988A6E093399

P478

Q58202813-B20653D1-6F4A-454C-82E6-89A6BD22E547

P50

Q58202813-10EE1A00-8A8D-4FF5-AE09-13878EA6363F

Q58202813-171AA4FD-C8BE-4158-9B0B-E043EA15AEDF

Q58202813-4475DBB8-1804-44C7-A546-B7ECF6D94EF1

P577

Q58202813-8D9D3FB9-D043-40B3-B4B8-E06C0B540505

P698

Q58202813-E7CE96D4-A866-4CDA-ADF2-5B74CADB7056

P921

Q58202813-fe30189e-d14d-4256-aae6-4be8f35cd45b

P356

JPET.107.130526

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

A neuronal microtubule-interac ...... e model of Alzheimer's disease

@en

P2093

Audrey J Gray

http://www.w3.org/2001/XMLSchema#string

Benjamin R Walker

http://www.w3.org/2001/XMLSchema#string

Chiho Hirata-Fukae

http://www.w3.org/2001/XMLSchema#string

Emmanuel Planel

http://www.w3.org/2001/XMLSchema#string

Hui-Fang Li

http://www.w3.org/2001/XMLSchema#string

Illana Gozes

http://www.w3.org/2001/XMLSchema#string

Laurent Lecanu

http://www.w3.org/2001/XMLSchema#string

Li Ma

http://www.w3.org/2001/XMLSchema#string

Paul S Aisen

http://www.w3.org/2001/XMLSchema#string

Yasuji Matsuoka

http://www.w3.org/2001/XMLSchema#string

P304

146-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.107.130526

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

325

http://www.w3.org/2001/XMLSchema#string

P50

Ottavio Arancio

P577

2008-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18199809

http://www.w3.org/2001/XMLSchema#string

P921